Trial site
Nmedis sp. z o.o.
Rzeszów, 35-323, PolandEU-13 widening countryNot linked to an institution yet
- 14running trials
- 3closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 24 trials
- Phase 41 trial
- Status
- Active, not recruiting8 trials
- Recruiting6 trials
- Completed3 trials
- Lead sponsor
- Hoffmann-La Roche9 trials
- Novartis Pharmaceuticals3 trials
- Zenas BioPharma (USA), LLC2 trials
- Biogen1 trial
- F. Hoffmann-La Roche AG1 trial
- and 1 more
Running trials
Active, not recruiting
Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis
2025-523726-40-00· Phase 3· F. Hoffmann-La Roche AG· Source
Recruiting
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· Phase 3· Novartis Pharma AG· Source
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578· Phase 3· Hoffmann-La Roche· Source
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
NCT04777331· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error